I am committed to providing my patients complete medical care that takes into account their physical and emotional wellbeing. When I approach my patients, I think of them as a whole, a person behind the story. I enjoy and cherish this special relationship and I always strive to give my patients the best care.

I believe that knowledge is power; I want my patients to be informed when they make decisions that involve their care and their lives. I achieve that by discussing the patient's case with the patient's referring oncologist and by consulting with my colleagues at Wilmot Cancer Center or at other institutions.

I am a firm believer that physician-patient trust is important to deliver effective and complete medical care. This trust develops based on the patient's own experience dealing with their medical team. My goal is to work closely with our medical team to help our patients deal with their illnesses.

My goal in choosing a career in treating cancer patients is to "make a difference" in their lives. I do that not only by doing my best to take care of my patients, but also by researching new ways to help our patients. Our current treatments are not optimal and certainly can be improved to help our patients have better outcomes, which is my ultimate goal in my research career.

Faculty Appointments

Professor - Department of Medicine, Hematology/Oncology (SMD)

Credentials

Residency & Fellowship

Fellowship, Blood & Marrow Transplantation, City of Hope National Medical Center. 2007 - 2008

Fellowship, Hematology & Oncology, University of Kansas Medical Center-Kansas City. 2004 - 2007

Residency, Internal Medicine, East Tennessee State University College of Medicine. 2002 - 2004

Internship, Internal Medicine, East Tennessee State University College of Medicine. 2001 - 2002

Internship, Internal Medicine, Bashir Hospital (Jordan). 1999 - 2000

Education

MBBS | University of Jordan (Jordan). 1999

Awards

Faculty Travel Award to present Abstract Poster. 2014

Faculty Travel Award to Present Abstract. 2011

2010 Best Abstract Award. 2010

Karl & Irene Eisemann Fellowship Award for best Hematology Paper. 2006

Caduceus Award Nominee. 2004

First Place Award, residents/fellows division, 18th Annual Student Research Forum, James H. Quillen College of Medicine. 2002

Research

Dr. Aljitawi's laboratory is primarily focused on studying the human hematopoietic stem cells and their interaction with their microenvironment. He utilizes this knowledge in studying translational research concepts that apply to patient care. Dr. Aljitawi's work has involved umbilical cord blood stem cells, Wharton's jelly mesenchymal stromal cells, Wharton's jelly matrix, and bone marrow mesenchymal stem cells. Dr. Aljitawi's main projects are:

1.Studying umbilical cord blood (UCB) CD34+ cell interaction with erythropoietin (EPO) as a soluble factor in UCB CD34+ microenvironment. Dr. Aljitawi has been investigating EPO signaling through EPO receptor (EPOR) effects on UCB CD34+ cell homing and engraftment. Dr. Aljitawi and his research team discovered that exposure to erythropoietin impairs UCB CD34+ cell homing to the bone marrow. To translate this finding to patient care, Dr. Aljitawi and his research team investigated the use of hyperbaric oxygen (HBO) as a modality to lower systemic EPO with the aim of improving UCB CD34+ cell homing and engraftment. This work in its entirety was recently published in Blood.

2. Developing in vitro 3D leukemia and myeloma models for chemotherapy drug testing: Dr. Aljitawi's lab has developed a 3D stromal-based co-culture model to grow leukemia and myeloma cells with stromal cells and used it to test the sensitivity of these cancer cells to chemotherapy. More recently, his lab has focused on studying decellularized Wharton's jelly matrix to create an extracellular matrix-based model to test leukemia cell responses to chemotherapy.

3. Studying the interactions between Wharton's jelly mesenchymal stromal cells and Wharton's jelly decellularized matrix for tissue regenerative medicine applications. Dr. Aljitawi's has been studying decellularized Wharton's jelly matrix as a scaffolding material for tissue regenerative applications, including wound and bone healing.

Research Lab

The Hematology and Transplantation Lab

Visit Research Lab Website

Clinical Trials

A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications (NMDP 10-CBA)

Lead Researcher: Omar S Aljitawi

This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.

Phase II Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplantation

Lead Researcher: Omar S Aljitawi

The UCB transplant is a type of stem cell transplant used to treat cancer of the blood or lymph glands. The UCB transplant has advantages over other types of transplants such as ease of obtaining the umbilical cord blood, absence of donor risks, redu...

Umbilical Cord Blood Transplantation from Unrelated Donors

Lead Researcher: Omar S Aljitawi

This study is a single-center, treatment protocol with 4 possible preparative regimens, designed to validate the process of umbilical cord blood stem cell transplantation at our institution.

Publications

Journal Articles

Remission of anti-TIF1? dermatomyositis after allogeneic hematopoietic stem cell transplant for myelodysplastic syndrome.

Bawany F, Tbakhi B, Mendler JH, Richardson CT, Bennett JM, Aljitawi OS

Blood advances.. 2020 November 244 (22):5698-5701. Epub 1900 01 01.

Stem cell homing: From physiology to therapeutics.

Liesveld JL, Sharma N, Aljitawi OS

Stem cells.. 2020 October 138 (10):1241-1253. Epub 07/21/2020.

Autologous Stem Cell Rescue recipient with neutrophil tissue delivery detected prior to blood engraftment: a case report.

Tbakhi B, Furqan F, Scott G, Liesveld JL, Aljitawi OS

EJHaem.. 2020 July 1 (1):330-333. Epub 08/07/2020.

Oral graft-versus-host disease: a pictorial review and a guide for dental practitioners.

Elad S, Aljitawi O, Zadik Y

International dental journal.. 2020 June 28 Epub 06/28/2020.

Use of hyperbaric oxygen in hematopoietic cell transplantation to aid post-transplant recovery.

Mina A, Aljitawi OS

Journal of comparative effectiveness research.. 2020 February 9 (3):149-153. Epub 01/29/2020.

Post-Transfusion Purpura Mimicking Idiopathic Thrombocytopenic Purpura: A Case Report.

Milito C, Masel D, Henrichs K, Schmidt AE, Kirkley S, Aljitawi O, Becker M, Blumberg N, Refaai MA

Laboratory medicine.. 2019 October 1050 (4):396-400. Epub 1900 01 01.

Results of the First Clinical Study in Humans That Combines Hyperbaric Oxygen Pretreatment with Autologous Peripheral Blood Stem Cell Transplantation.

Lipe B, Divine C, Abhyankar S, Singh AK, Ganguly S, Lin TL, Baran A, Cantilena AR, Bhatti S, Shune L, Abdelhakim H, McGuirk J, Allin D, Aljitawi OS

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.. 2019 September 25 (9):1713-1719. Epub 06/03/2019.

VCAM-1+ macrophages usher hematopoietic stem and progenitor cell to vascular niche "hotspots".

Aljitawi OS, Chiu YG

Annals of translational medicine.. 2019 July 7 (Suppl 3):S116. Epub 1900 01 01.

Decellularized Wharton jelly matrix: a biomimetic scaffold for ex vivo hematopoietic stem cell culture.

Li D, Chiu G, Lipe B, Hopkins RA, Lillis J, Ashton JM, Paul S, Aljitawi OS

Blood advances.. 2019 April 93 (7):1011-1026. Epub 1900 01 01.

Long-term results of a pilot study evaluating hyperbaric oxygen therapy to improve umbilical cord blood engraftment.

Mina A, Shune L, Abdelhakim H, Lin TL, Ganguly S, Baran A, Singh A, Abhyankar S, McGuirk JP, Allin D, Aljitawi OS

Annals of hematology.. 2019 February 98 (2):481-489. Epub 10/31/2018.

A novel extracellular matrix-based leukemia model supports leukemia cells with stem cell-like characteristics.

Li D, Lin TL, Lipe B, Hopkins RA, Shinogle H, Aljitawi OS

Leukemia research.. 2018 September 72 :105-112. Epub 08/16/2018.

Hyperbaric oxygen treatment effects on in vitro cultured umbilical cord blood CD34 cells.

Cheung KY, Berry A, Li D, Aljitawi OS

Cytotherapy.. 2018 January 20 (1):87-94. Epub 10/14/2017.

Wharton's Jelly Matrix Decellularization for Tissue Engineering Applications.

Converse GL, Li D, Buse EE, Hopkins RA, Aljitawi OS

Methods in molecular biology.. 2018 1577 :25-33. Epub 1900 01 01.

Correlation between markers of bone metabolism and vitamin D levels in patients with monoclonal gammopathy of undetermined significance (MGUS).

Lipe B, Kambhampati S, Veldhuizen PV, Yacoub A, Aljitawi O, Mikhael J

Blood cancer journal.. 2017 December 147 (12):646. Epub 12/14/2017.

Erythropoietin in umbilical cord blood transplantation: defining the role and implications.

Aljitawi OS, Laughlin M, Broxmeyer H

Expert review of hematology.. 2017 August 10 (8):675-677. Epub 07/12/2017.

Erythropoietin in umbilical cord blood transplantation: Defining the role and implications

Aljitawi, O.

Expert Review of Hematology. 2017; .

Decellularized Wharton's Jelly from human umbilical cord as a novel 3D scaffolding material for tissue engineering applications.

Jadalannagari S, Converse G, McFall C, Buse E, Filla M, Villar MT, Artigues A, Mellot AJ, Wang J, Detamore MS, Hopkins RA, Aljitawi OS

PloS one.. 2017 12 (2):e0172098. Epub 02/21/2017.

Erythropoietin modulation is associated with improved homing and engraftment after umbilical cord blood transplantation.

Aljitawi OS, Paul S, Ganguly A, Lin TL, Ganguly S, Vielhauer G, Capitano ML, Cantilena A, Lipe B, Mahnken JD, Wise A, Berry A, Singh AK, Shune L, Lominska C, Abhyankar S, Allin D, Laughlin M, McGuirk JP, Broxmeyer HE

Blood.. 2016 December 22128 (25):3000-3010. Epub 10/19/2016.

A novel hematopoietic progenitor cell mobilization regimen, utilizing bortezomib and filgrastim, for patients undergoing autologous transplant.

Abhyankar S, Lubanski P, DeJarnette S, Merkel D, Bunch J, Daniels K, Aljitawi O, Lin T, Ganguly S, McGuirk J

Journal of clinical apheresis.. 2016 December 31 (6):559-563. Epub 03/04/2016.

A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium study.

Kirschbaum MH, Frankel P, Synold TW, Xie Z, Yen Y, Popplewell L, Chen R, Aljitawi O, Tuscano JM, Chan KK, Newman EM

Leukemia & lymphoma.. 2016 October 57 (10):2307-14. Epub 02/19/2016.

Potential mechanisms underlying ectodermal differentiation of Wharton's jelly mesenchymal stem cells.

Jadalannagari S, Berry AM, Hopkins RA, Bhavsar D, Aljitawi OS

Biochemical and biophysical research communications.. 2016 September 16478 (2):831-7. Epub 08/05/2016.

Evaluation of cytomegalovirus reactivation and tolerability in seropositive umbilical cord transplant patients after implementation of an intensive prevention strategy.

Rinehart M, Hochard E, Rockey M, Abhyankar S, Ganguly S, Lin T, McGuirk J, Shune L, Singh A, Aljitawi O

Hematology/oncology and stem cell therapy.. 2016 September 9 (3):105-11. Epub 03/17/2016.

Fatal GvHD induced by PD-1 inhibitor pembrolizumab in a patient with Hodgkin's lymphoma.

Singh AK, Porrata LF, Aljitawi O, Lin T, Shune L, Ganguly S, McGuirk JP, Abhyankar S

Bone marrow transplantation.. 2016 September 51 (9):1268-70. Epub 04/25/2016.

Effect of extracorporeal photopheresis on lung function decline for severe bronchiolitis obliterans syndrome following allogeneic stem cell transplantation.

Brownback KR, Simpson SQ, Pitts LR, Polineni D, McGuirk JP, Ganguly S, Aljitawi OS, Lin TL, Singh A, Abhyankar S

Journal of clinical apheresis.. 2016 August 31 (4):347-52. Epub 05/29/2015.

Adequacy of peripheral blood stem cell mobilization in patients with relapsed B-cell non-Hodgkin lymphoma treated with bendamustine.

Iliff A, Divine C, Diaz F, Aljitawi O, Abhayankar S, McGuirk J, Ganguly S

Leukemia & lymphoma.. 2016 May 57 (5):1189-90. Epub 10/12/2015.

Propylene glycol-free melphalan as conditioning regimen for autologous transplantation in myeloma.

Aljitawi OS, Hari P

International journal of hematologic oncology.. 2016 May 5 (1):5-10. Epub 05/31/2016.

Tolerability and outcome of once weekly liposomal amphotericin B for the prevention of invasive fungal infections in hematopoietic stem cell transplant patients with graft-versus-host disease.

Luu Tran H, Mahmoudjafari Z, Rockey M, Henry D, Grauer D, Aljitawi O, Abhyankar S, Ganguly S, Lin T, McGuirk J

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.. 2016 April 22 (2):228-34. Epub 12/03/2014.

Pokhrel SD, Persons DL, Aljitawi OS

Case reports in hematology.. 2016 2016 :8628507. Epub 02/02/2016.

A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation.

Hari P, Aljitawi OS, Arce-Lara C, Nath R, Callander N, Bhat G, Allen LF, Stockerl-Goldstein K

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.. 2015 December 21 (12):2100-2105. Epub 08/29/2015.

Outcomes for newly diagnosed patients with acute myeloid leukemia dosed on actual or adjusted body weight.

Bray WM, Bivona C, Rockey M, Henry D, Grauer D, Abhyankar S, Aljitawi O, Ganguly S, McGuirk J, Singh A, Lin TL

Cancer chemotherapy and pharmacology.. 2015 October 76 (4):691-7. Epub 08/01/2015.

Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia.

Ciurea SO, Zhang MJ, Bacigalupo AA, Bashey A, Appelbaum FR, Aljitawi OS, Armand P, Antin JH, Chen J, Devine SM, Fowler DH, Luznik L, Nakamura R, O'Donnell PV, Perales MA, Pingali SR, Porter DL, Riches MR, Ringdén OT, Rocha V, Vij R, Weisdorf DJ, Champlin RE, Horowitz MM, Fuchs EJ, Eapen M

Blood.. 2015 August 20126 (8):1033-40. Epub 06/30/2015.

Ectodermal Differentiation of Wharton's Jelly Mesenchymal Stem Cells for Tissue Engineering and Regenerative Medicine Applications.

Jadalannagari S, Aljitawi OS

Tissue engineering. Part B, Reviews.. 2015 June 21 (3):314-22. Epub 01/30/2015.

Rates of complete diagnostic testing for patients with acute myeloid leukemia.

Lin TL, Williams T, He J, Aljitawi OS, Ganguly S, Abhyankar S, Fleming A, Male H, McGuirk JP

Cancer medicine. 2015 April 4 (4):519-22. Epub 01/26/2015.

Routine radiographic screening after completion of initial chemotherapy and relapse-free survival after transplant in patients with relapsed lymphoma.

Ganguly S, McRae J, He J, Divine C, Abhyankar S, Aljitawi O, McGuirk JP

Leukemia & lymphoma.. 2015 February 56 (2):518-9. Epub 07/15/2014.

In Vivo Purging May Not be Required in the Era of Universal Use of Rituximab Containing Chemo-Immunotherapy in Patients with Follicular and Mantle Cell Lymphoma: A Single Center Experience.

Singh, AK; Divine, C; Aljitawi, O; Abhyankar, S; McQuirk, JP; Ganguly, S.

Bio of Blood and Marrow Transp. 2015; 21(2 Supp): S135-S136.

Combined use of multiday palonosetron with aprepitant and low-dose dexamethasone in prevention of nausea and emesis among patients with multiple myeloma and lymphoma undergoing autologous hematopoietic stem cell transplant: A pilot study.

Deauna-Limayo D, Aljitawi OS, Ganguly S, Abhyankar S, Wick JA, McGuirk JP

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.. 2014 August 20 (4):263-9. Epub 09/04/2013.

Phase IIa cross-over study of propylene glycol-free melphalan (LGD-353) and alkeran in multiple myeloma autologous transplantation.

Aljitawi OS, Ganguly S, Abhyankar SH, Ferree M, Marks R, Pipkin JD, McGuirk JP

Bone marrow transplantation.. 2014 August 49 (8):1042-5. Epub 06/09/2014.

Intestinal ischemia after allogeneic stem cell transplantation: a report of four cases.

Prochaska L, Vacek J, Madan R, Abhyankar S, Ganguly S, McGuirk JP, Lin TL, Aljitawi OS

Transplantation proceedings.. 2014 June 46 (5):1536-9. Epub 1900 01 01.

Pulmonary manifestations of the pre-engraftment syndrome after umbilical cord blood transplantation.

Brownback KR, Simpson SQ, McGuirk JP, Lin TL, Abhyankar S, Ganguly S, Aljitawi OS

Annals of hematology.. 2014 May 93 (5):847-54. Epub 12/18/2013.

Rituximab as a treatment for factor VIII inhibitor in a patient with chronic GVHD.

Wieliczka ML, Ganguly S, Abhyankar S, Lin T, McGuirk JP, Aljitawi OS

Bone marrow transplantation.. 2014 April 49 (4):588. Epub 01/20/2014.

A novel three-dimensional stromal-based model for in vitro chemotherapy sensitivity testing of leukemia cells.

Aljitawi OS, Li D, Xiao Y, Zhang D, Ramachandran K, Stehno-Bittel L, Van Veldhuizen P, Lin TL, Kambhampati S, Garimella R

Leukemia & lymphoma.. 2014 February 55 (2):378-91. Epub 05/15/2013.

Hyperbaric oxygen improves engraftment of ex-vivo expanded and gene transduced human CD34? cells in a murine model of umbilical cord blood transplantation.

Aljitawi OS, Xiao Y, Eskew JD, Parelkar NK, Swink M, Radel J, Lin TL, Kimler BF, Mahnken JD, McGuirk JP, Broxmeyer HE, Vielhauer G

Blood cells, molecules & diseases.. 2014 January 52 (1):59-67. Epub 08/14/2013.

Inflammatory response following neutrophil recovery postchemotherapy in acute myeloid leukemia cases without evidence of infection: role of homing of neutrophils.

Pawar RD, Williams T, Khera R, Eid A, Aljitawi OS, Dusing RW

Journal of blood medicine.. 2014 5 :37-41. Epub 03/10/2014.

Skin Recurrence of Transformed Mycosis Fungoides Postumbilical Cord Blood Transplant despite Complete Donor Chimerism.

Pawar R, Kasi Loknath Kumar A, Woodroof J, Cui W, McGuirk J, Abhyankar S, Ganguly S, Singh A, Lin T, Aljitawi O

Case reports in hematology.. 2014 2014 :743856. Epub 12/11/2014.

Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia.

Williams CB, Kambhampati S, Fiskus W, Wick J, Dutreix C, Ganguly S, Aljitawi O, Reyes R, Fleming A, Abhyankar S, Bhalla KN, McGuirk JP

Pharmacotherapy.. 2013 December 33 (12):1341-52. Epub 06/24/2013.

Decitabine in patients with relapsed acute myeloid leukemia (AML) after allogeneic stem cell transplantation (allo-SCT).

Ganguly S, Amin M, Divine C, Aljitawi OS, Abhyankar S, McGuirk JP

Annals of hematology.. 2013 April 92 (4):549-50. Epub 10/31/2012.

Generating CK19-positive cells with hair-like structures from Wharton's jelly mesenchymal stromal cells.

Aljitawi OS, Xiao Y, Zhang D, Stehno-Bittel L, Garimella R, Hopkins RA, Detamore MS

Stem cells and development.. 2013 January 122 (1):18-26. Epub 10/19/2012.

Bendamustine associated with irreversible ascending paralysis.

Alhafez A, Aljitawi OS, Lin TL, Ganguly S, Abhyankar S, McGuirk JP

Case reports in hematology.. 2013 2013 :931519. Epub 02/27/2013.

First case of donor transmitted non-leukemic promyelocytic sarcoma.

Williams T, Aljitawi OS, Moussa R, McHugh S, Dusing R, Abraha J, Yarlagadda SG

Leukemia & lymphoma.. 2012 December 53 (12):2530-4. Epub 07/09/2012.

Research Highlights: Highlights from the latest articles in molecular profiling and prognosis in acute myeloid leukemia.

Aljitawi OS, Lin TL

Personalized medicine.. 2012 September 9 (7):679-682. Epub 1900 01 01.

Lymphoma-associated hemophagocytic lymphohistiocytosis.

Aljitawi OS, Boone JM

Blood.. 2012 August 2120 (5):932. Epub 1900 01 01.

A risk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor.

Abhyankar S, DeJarnette S, Aljitawi O, Ganguly S, Merkel D, McGuirk J

Bone marrow transplantation.. 2012 April 47 (4):483-7. Epub 07/04/2011.

Ex vivo expansion of umbilical cord blood: where are we?

Aljitawi OS

International journal of hematology.. 2012 April 95 (4):371-9. Epub 03/23/2012.

BU, melphalan and thiotepa as a preparative regimen for auto-transplantation in Hodgkin's disease.

Ganguly S, Jain V, Divine C, Aljitawi O, Abhyankar S, McGuirk J

Bone marrow transplantation.. 2012 February 47 (2):311-2. Epub 04/04/2011.

Multiple myeloma preparative regimens for high-dose therapy and autologous transplantation: what's new?

Aljitawi OS, McGuirk JP

Journal of comparative effectiveness research.. 2012 January 1 (1):57-70. Epub 1900 01 01.

Coexistent Non-Hodgkin's Lymphoma and Renal Cell Carcinoma in a Patient with Von Hipple-Lindau Disease: A Case Report.

Aljitawi, OS; Allen M; Zhang D; Dasouki M; Abhyabjar S, et al.

J Blood Lymph. 2012; .

Prophylactic use of zoledronic acid to prevent early bone loss is safe and feasible in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation.

Ganguly S, Divine CL, Aljitawi OS, Abhyankar S, McGuirk JP, Graves L

Clinical transplantation.. 2012 26 (3):447-53. Epub 10/17/2011.

Umbilical cord graft-versus-leukemia effect induces remission without the price of graft-versus-host disease: the possible role of NK cells.

Aljitawi OS, Coats A, Zhang D, Ganguly S, Abhyankar S, Lin T, McGuirk JP

Clinical transplantation.. 2012 26 (5):663-4. Epub 09/02/2012.

Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts.

Brunstein CG, Fuchs EJ, Carter SL, Karanes C, Costa LJ, Wu J, Devine SM, Wingard JR, Aljitawi OS, Cutler CS, Jagasia MH, Ballen KK, Eapen M, O'Donnell PV,

Blood.. 2011 July 14118 (2):282-8. Epub 04/28/2011.

Late-onset intestinal perforation in the setting of posttransplantation microangiopathy: a case report.

Aljitawi OS, Rodriguez L, Madan R, Ganguly S, Abhyankar S, McGuirk JP

Transplantation proceedings.. 2010 November 42 (9):3892-3. Epub 1900 01 01.

Low-dose cidofovir in the treatment of symptomatic BK virus infection in patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis of an algorithmic approach.

Ganguly N, Clough LA, Dubois LK, Mcguirk JP, Abhyankar S, Aljitawi OS, O'Neal N, Divine CL, Ganguly S

Transplant infectious disease : an official journal of the Transplantation Society.. 2010 October 12 (5):406-11. Epub 1900 01 01.

Blastic plasmacytoid dendritic cell neoplasm should be treated with acute leukemia type induction chemotherapy and allogeneic stem cell transplantation in first remission.

Male HJ, Davis MB, McGuirk JP, Abhyankar S, Aljitawi OS, Zhang D, Ganguly S

International journal of hematology.. 2010 September 92 (2):398-400. Epub 08/11/2010.

A patient with facial and neck swelling, dyspnea, and dysphagia.

Copeland B, Aljitawi O, Fitzgerald SM, Chi DS, Krishnaswamy G

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.. 2005 December 95 (6):510-7. Epub 1900 01 01.

Bilateral upper extremity thrombophlebitis related to intravenous amiodarone: a case report.

Aljitawi O, Shabaneh B, Whitaker J

Southern medical journal.. 2005 August 98 (8):814-6. Epub 1900 01 01.

Serologically documented loracarbef (Lorabid)-induced immune thrombocytopenia.

Aljitawi OS, Krishnan K, Curtis BR, Bougie DW, Aster RH

American journal of hematology.. 2003 May 73 (1):41-3. Epub 1900 01 01.

Advances in Individualized Prognosis in Acute Myeloid Leukemia.

Aljitawi, OS; Lin, T.

Personalized Medicine. 9(7): 679-682.

Potential Mechanisms Underlying Ectodermal Differentiation of Wharton's Jelly Mesenchymal Stem Cells.

Jadalannagari, S; Berry, AM; Hopkins, RA; Bhavsar, D; Aljitasi, OS;.

BBRC. .

Books

Decellularized Scaffolds and Organogenesis (2017)

Chapter: Wharton's jelly matrix decellularization for tissue engineering applications

Authors: Converse, G.L; Li, D; E. Buse, E.E.; Hopkins, R.A.; and Aljitawi, O.S.

Publisher: Springer Protocols 2017

Mast Cells, Methods and Protocols (2005)

Chapter: The human Mast Cell

Authors: Guha Krishnaswamy, Omar Aljitawi, and David S. Chi.

Publisher: Humana Press 2005

Ratings & Comments

At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information. Learn more about our survey process.

Ratings

During this visit, did this provider spend enough time with you?

5.0

During this visit, did this provider show respect for what you had to say?

5.0

During this visit did this provider give you easy to understand information about these health questions or concerns?

4.9

During this visit, did this provider listen carefully to you?

5.0

During this visit, did this provider explain things in a way that was easy to understand?

4.9

Patient Comments

Dr. Omar Aljitawi is an excellent doctor. Thorough, professional, personable and caring.

Sep 26, 2024

Always fun to see Dr. Al!

Sep 06, 2024

Excellent care

Aug 28, 2024

Excellent care from the Doctor and Staff.

Aug 22, 2024

5.0

I am very pleased with my treatment by Dr. Aljitawi.

May 17, 2024

5.0

Excellent

Mar 15, 2024

5.0

I have already recommended them

Sep 20, 2023

5.0

Dr. Aljitawi is EXCELLENT.

Sep 12, 2023

5.0

Dr. Aljitawi is always thorough.

Aug 10, 2023

5.0

Dr. Aljitawi was excellent.

May 05, 2023

5.0

We are very happy with Dr. Aljitawi!

Apr 04, 2023

5.0

Dr. Aljitawi was very informative of the next steps in my care He even called my husband together and explained it to him. We were very appreciative of that.

Jan 05, 2023

5.0

Dr. Aljitawi is wonderful. He always explains everything thoroughly and in terms I can understand.

Dec 30, 2022

5.0

The doctor and his team are great and I appreciate them very much. But I hope not to have to recommend bone marrow transplant for others!

Sep 27, 2022

5.0

Dr. is outstanding.

May 25, 2022

5.0

Dr. Aljitawi is excellent and staff the BEST!!

Apr 21, 2022

5.0

Dr. Omar Aljitawi is very pleasant and helpful explaining my condition as I progress. Very clean and gives me all my options.

Mar 23, 2022

5.0

Dr. Aljitawi is excellent and someone I trust completely

Feb 11, 2022

5.0

Dr. Aljitawi is an EXCELLENT provider.

Feb 03, 2022